Q1 EPS Estimates for Stoke Therapeutics Increased by Wedbush

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research note issued on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will post earnings per share of ($0.57) for the quarter, up from their prior forecast of ($0.58). The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. Wedbush also issued estimates for Stoke Therapeutics’ Q3 2025 earnings at ($0.62) EPS, Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.37) EPS, FY2026 earnings at ($3.02) EPS, FY2027 earnings at ($3.13) EPS, FY2028 earnings at ($2.69) EPS and FY2029 earnings at ($2.01) EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%. The company had revenue of $22.61 million for the quarter, compared to analysts’ expectations of $4.20 million.

A number of other equities analysts have also recently issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Chardan Capital reissued a “buy” rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. Finally, HC Wainwright reissued a “buy” rating and issued a $47.00 price target on shares of Stoke Therapeutics in a research report on Wednesday. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Stoke Therapeutics presently has a consensus rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Stock Down 2.2 %

Shares of STOK opened at $8.15 on Friday. Stoke Therapeutics has a 12-month low of $5.93 and a 12-month high of $17.58. The business’s fifty day moving average is $9.47 and its 200 day moving average is $11.45. The stock has a market cap of $431.68 million, a P/E ratio of -3.88 and a beta of 0.99.

Insider Buying and Selling

In other Stoke Therapeutics news, Director Edward M. Md Kaye sold 10,382 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the completion of the transaction, the director now owns 148,253 shares in the company, valued at $1,285,353.51. This trade represents a 6.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 16,532 shares of company stock valued at $143,332. 11.30% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in STOK. Toronto Dominion Bank bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $35,001,000. RTW Investments LP boosted its position in shares of Stoke Therapeutics by 10.1% during the 4th quarter. RTW Investments LP now owns 5,123,525 shares of the company’s stock valued at $56,512,000 after acquiring an additional 471,240 shares during the last quarter. Norges Bank bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $3,472,000. Tang Capital Management LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $3,309,000. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Stoke Therapeutics during the 4th quarter valued at about $3,218,000.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.